Helen Millns

2.7k total citations · 2 hit papers
16 papers, 2.0k citations indexed

About

Helen Millns is a scholar working on Epidemiology, Molecular Biology and Surgery. According to data from OpenAlex, Helen Millns has authored 16 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Epidemiology, 4 papers in Molecular Biology and 3 papers in Surgery. Recurrent topics in Helen Millns's work include Urinary Tract Infections Management (6 papers), Antibiotic Resistance in Bacteria (2 papers) and Pediatric Urology and Nephrology Studies (2 papers). Helen Millns is often cited by papers focused on Urinary Tract Infections Management (6 papers), Antibiotic Resistance in Bacteria (2 papers) and Pediatric Urology and Nephrology Studies (2 papers). Helen Millns collaborates with scholars based in United Kingdom, United States and Germany. Helen Millns's co-authors include R. C. Turner, Rury R. Holman, Irene Stratton, Susan E. Manley, David R. Matthews, H. A. W. Neil, F M Ashcroft, H Sakura, V. Horton and Nelson M.S. Wat and has published in prestigious journals such as The Lancet, Diabetes and American Journal of Epidemiology.

In The Last Decade

Helen Millns

16 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23)

1998 1.5k citations R. C. Turner, Helen Millns et al. BMJ profile →
Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials

2024 44 citations Florian Wagenlehner, Caroline Perry et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Helen Millns United Kingdom	10	1.3k	714	517	399	247	16	2.0k
Maria Luiza Caramori United States	16	852 0.7×	368 0.5×	395 0.8×	555 1.4×	259 1.0×	32	2.7k
Sreenivasa Rao Kondapally Seshasai United Kingdom	12	1.0k 0.8×	588 0.8×	691 1.3×	366 0.9×	305 1.2×	21	2.2k
Esther Ooi Australia	28	937 0.7×	1.1k 1.5×	539 1.0×	450 1.1×	431 1.7×	81	2.2k
Juan F. Ascaso Spain	25	1.1k 0.8×	945 1.3×	446 0.9×	392 1.0×	467 1.9×	147	2.6k
Bernt Johan von Scholten Denmark	29	899 0.7×	584 0.8×	615 1.2×	481 1.2×	166 0.7×	74	2.0k
Triantafyllos Didangelos Greece	24	674 0.5×	471 0.7×	481 0.9×	204 0.5×	339 1.4×	83	1.8k
Laura Schreier Argentina	27	743 0.6×	438 0.6×	409 0.8×	233 0.6×	444 1.8×	115	1.9k
Valdis Pīrāgs Latvia	22	1.0k 0.8×	527 0.7×	243 0.5×	877 2.2×	335 1.4×	86	2.1k
William L. Isley United States	23	1.0k 0.8×	382 0.5×	454 0.9×	366 0.9×	212 0.9×	51	1.8k
Peter Fasching Austria	24	664 0.5×	380 0.5×	348 0.7×	306 0.8×	203 0.8×	89	2.0k

Countries citing papers authored by Helen Millns

Since Specialization

Citations

This map shows the geographic impact of Helen Millns's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helen Millns with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helen Millns more than expected).

Fields of papers citing papers by Helen Millns

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helen Millns. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helen Millns. The network helps show where Helen Millns may publish in the future.

Co-authorship network of co-authors of Helen Millns

This figure shows the co-authorship network connecting the top 25 collaborators of Helen Millns. A scholar is included among the top collaborators of Helen Millns based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helen Millns. Helen Millns is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Scangarella-Oman, Nicole E., John Breton, D. J. Brown, et al.. (2025). Efficacy and in vitro activity of gepotidacin against bacterial uropathogens, including drug-resistant phenotypes, in females with uncomplicated urinary tract infections: results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3). Antimicrobial Agents and Chemotherapy. 69(10). e0164024–e0164024. 1 indexed citations

Wagenlehner, Flo ri an, Caroline Perry, Thomas M. Hooton, et al.. (2025). Plain language summary: efficacy and safety of gepotidacin, a new oral antibiotic, compared with nitrofurantoin, a commonly used oral antibiotic, for treating uncomplicated urinary tract infection. Future Microbiology. 20(4). 265–275. 1 indexed citations

Wagenlehner, Flo ri an, Caroline Perry, Thomas M. Hooton, et al.. (2024). Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials. The Lancet. 403(10428). 741–755. 44 indexed citations breakdown →

Wagenlehner, Flo ri an, Caroline Perry, Thomas M. Hooton, et al.. (2023). P31 Efficacy and safety of oral gepotidacin in the treatment of uncomplicated urinary tract infection: results of two randomized, multicentre Phase 3 trials (EAGLE-2 and EAGLE-3). JAC-Antimicrobial Resistance. 5(Supplement_3). 2 indexed citations

Perry, Caroline, Nicole E. Scangarella-Oman, Helen Millns, et al.. (2023). Efficacy and Safety of Gepotidacin as Treatment of Uncomplicated Urogenital Gonorrhea (EAGLE-1): Design of a Randomized, Comparator-Controlled, Phase 3 Study. Infectious Diseases and Therapy. 12(9). 2307–2320. 16 indexed citations

Hooton, Thomas M., et al.. (2023). 2832. Gepotidacin Efficacy in E. coli Drug-Resistant Phenotypes: A Pooled Analysis of the EAGLE-2 and EAGLE-3 Randomized Controlled Trials in Uncomplicated Urinary Tract Infection. Open Forum Infectious Diseases. 10(Supplement_2). 1 indexed citations

Mohan, Divya, Harry B. Rossiter, Henrik Watz, et al.. (2022). Selective androgen receptor modulation for muscle weakness in chronic obstructive pulmonary disease: a randomised control trial. Thorax. 78(3). 258–266. 19 indexed citations

Richards, Duncan, Helen Millns, Louise Cookson, & Mary Ann Lukas. (2022). An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study. Orphanet Journal of Rare Diseases. 17(1). 259–259. 7 indexed citations

Millns, Helen, R Bergemann, Elizabeth J. Ackermann, Brett P. Monia, & Mary Ann Lukas. (2015). A phase 3 clinical trial with ISIS-TTRRx, a 2nd-generation antisense oligonucleotide targeting transthyretin (TTR), for the treatment of TTR amyloid cardiomyopathy. Orphanet Journal of Rare Diseases. 10(Suppl 1). P8–P8. 2 indexed citations

10.

Ratti, Emiliangelo, P. Bettica, Robert Alexander, et al.. (2013). Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies. Journal of Psychopharmacology. 27(5). 424–434. 55 indexed citations

11.

Turner, R. C., Helen Millns, H. A. W. Neil, et al.. (1998). Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ. 316(7134). 823–828. 1501 indexed citations breakdown →

12.

Turner, R. C., Helen Millns, & Rury R. Holman. (1997). Coronary heart disease and risk factors in NIDDM experience from the United Kingdom Prospective Diabetes Study. Diabetologia. 40(0). S121–S122. 16 indexed citations

13.

Inoue, Hiroshi, Jorge Ferrer, Margaret Warren-Perry, et al.. (1997). Sequence Variants in the Pancreatic Islet β-Cell Inwardly Rectifying K+ Channel Kir6.2 (Bir) Gene: Identification and Lack of Role in Caucasian Patients with NIDDM. Diabetes. 46(3). 502–507. 87 indexed citations

14.

Sakura, H, Nelson M.S. Wat, V. Horton, et al.. (1996). Sequence variations in the human Kir6.2 gene, a subunit of the beta-cell ATP-sensitive K-channel: no association with NIDDM in white caucasian subjects or evidence of abnormal function when expressed in vitro. Diabetologia. 39(10). 1233–1236. 104 indexed citations

15.

Inoue, Hiroshi, Jorge Ferrer, Cris M. Welling, et al.. (1996). Sequence Variants in the Sulfonylurea Receptor (SUR) Gene Are Associated With NIDDM in Caucasians. Diabetes. 45(6). 825–831. 110 indexed citations

16.

Millns, Helen, Mark Woodward, & C Bolton-Smith. (1995). Is it Necessary to Transform Nutrient Variables prior to Statistical Analyses?. American Journal of Epidemiology. 141(3). 251–262. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact